New combo therapy tested for tough head & neck cancer
NCT ID NCT03267498
Summary
This study tested whether adding an immunotherapy drug called nivolumab to standard chemotherapy and radiation treatment could better control nasopharyngeal cancer. It involved 40 adults with stage II-IVB cancer to see if the combined treatment was feasible and effective. The main goal was to see if patients could complete the full course of this new regimen and to measure how well the cancer responded one year after treatment ended.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National University Hospital Singapore
Singapore, 119074, Singapore
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.